Evidence map›Paper›PMID 41680766›Full record

ArticleBMC medicine2026

An autonomous siRNA delivery system targeting NLRP3: implications in Parkinson's disease.

Lishan Lin, Zhizong Li, Fengjuan Su, Heng Huang, Sen Huang, Weineng Chen, Jiamin Zheng, Hailun Yu, Frederic Zhentao Li, Xinghu Du and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Lishan Lin *Department of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China.
Zhizong Li *The Second People's Hospital of Changzhou, The Third Affiliated Hospital of Nanjing Medical University, Changzhou Medical Center, Nanjing Medical University, Changzhou, Jiangsu, 211166, China.
Fengjuan Su *Department of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China.
Heng HuangDepartment of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China.
Sen HuangDepartment of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China.
Weineng ChenDepartment of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China.
Jiamin ZhengNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, NJU Advanced Institute of Life Sciences (NAILS), School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.
Hailun YuCarrier Biomed (Suzhou) Co.,Ltd. , Jin ji Lake Avenue, Industrial Park, Suzhou, Jiangsu, 215000, China.
Frederic Zhentao LiCarrier Biomed (Suzhou) Co.,Ltd. , Jin ji Lake Avenue, Industrial Park, Suzhou, Jiangsu, 215000, China.
Xinghu DuNanjing Drum Tower Hospital Center of Molecular Diagnostic and Therapy, State Key Laboratory of Pharmaceutical Biotechnology, Jiangsu Engineering Research Center for MicroRNA Biology and Biotechnology, NJU Advanced Institute of Life Sciences (NAILS), School of Life Sciences, Nanjing University, Nanjing, Jiangsu, 210023, China.
Yucheng LiDepartment of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China.
Lei CaiGuangdong Provincial Biotechnology Research Institute, Guangzhou, Guangdong, 510663, China.
Huajing YouDepartment of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China.
Yu ZhangGuangdong Provincial Biotechnology Research Institute, Guangzhou, Guangdong, 510663, China.
Zhong PeiDepartment of Neurology, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, Sun Yat-Sen University, Guangzhou, Guangdong, 510080, China. peizhong@mail.sysu.edu.cn.

Funding

Guangdong Province International Cooperation Base for Early Intervention and Functional Rehabilitation of Neurological Diseases 2020A0505020004Guangdong Provincial Clinical Research Center for Neurological Diseases 2020B1111170002National Key Research and Development Program of China 2022YFA1104900National Natural Science Foundation of China No. 82271266, No. 82071255, No. 81873751
6 · The paper itself

Abstract

backgroundParkinson's disease is the second most common neurodegenerative disease worldwide, with no disease-modifying therapy available. NLRP3 inflammasome-linked neuroinflammation is involved in the onset and progression of Parkinson's disease; therefore, inhibition of the NLRP3 inflammasome may provide a new gene therapy option.

methodsIn the present study, we developed a CMV-RVG-9dR-siR

resultsCompared with the original RVG guide peptide, the modified RVG-9dR in the synthetic construct delivered higher levels of NLRP3-siRNA to the deep brain structures (substantia nigra and striatum). Injection of this modified synthetic construct attenuated MPTP- and α-synuclein-induced NLRP3 inflammasome activation, microgliosis, dopaminergic neurodegeneration, and motor impairments in the animal models for Parkinson's disease.

conclusionsOur study describes a modified synthetic construct that could improve the efficacy of siRNA delivery to deep brain structures and presents proof-of-principle evidence showing that genetic knockdown of NLRP3 could represent a new therapeutic strategy to treat Parkinson's disease and other neuroinflammation-related brain disorders.

Indexed as

NLR Family, Pyrin Domain-Containing 3 ProteinParkinson DiseaseRNA, Small InterferingAnimalsDisease Models, AnimalGenetic TherapyInflammasomesMaleMiceMice, Inbred C57BLInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseRNA, Small InterferingDelivery efficacyExtracellular vesiclesNLRP3Parkinson’s diseaseRVG-9dR

Identifiers

PMID41680766
PMCPMC12997903

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.